Insulin Sensitivity during Combined Androgen Blockade for Prostate Cancer
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
CONTEXT: GnRH agonists markedly increase fat mass in men with prostate cancer, but little is known about the effects of treatment on insulin sensitivity. OBJECTIVE: The objective of the study was to assess the effects of short-term GnRH agonist treatment on insulin sensitivity. DESIGN: This was a prospective 12-wk study. SETTING: The study was conducted at a general clinical research center. PATIENTS OR OTHER PARTICIPANTS: We studied 25 men with locally advanced or recurrent prostate cancer, no radiographic evidence of metastases, no history of diabetes mellitus, and no evidence of diabetes mellitus at baseline visit. INTERVENTION: Leuprolide depot and bicalutamide were used in the study. MAIN OUTCOME MEASURES: Oral glucose tolerance tests and body composition assessment by dual-energy x-ray absorptiometry were performed at baseline and wk 12. The primary study outcome was change in insulin sensitivity index. RESULTS: Mean (+/- se) percentage fat body mass increased by 4.3 +/- 1.3% from baseline to wk 12 (P = 0.002). Insulin sensitivity index decreased by 12.9 +/- 7.6% (P = 0.02). Insulin sensitivity by homeostatic model assessment decreased by 12.8 +/- 5.9% (P = 0.02). Fasting plasma insulin levels increased by 25.9 +/- 9.3% (P = 0.04). Mean glycosylated hemoglobin also increased significantly (P < 0.001). CONCLUSIONS: Short-term treatment with leuprolide and bicalutamide significantly increased fat mass and decreased insulin sensitivity in men with prostate cancer. These observations suggest that GnRH agonists may increase the risk of diabetes mellitus and cardiovascular disease in older men.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 4×
“The whole-body ISI was calculated from fasting plasma insulinandglucoseconcentrationsandmeanplasmainsulinandglucose concentrations during the OGTT, with ISI 10,000/square root of (fasting plasma glucose fasting plasma insulin) (mean OGTT glucose mean OGTT insulin) ( 18 ).”
BackgroundMethodResultInfluentialDeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,535 · cited 1×
“The observed increase in HDL cholesterol levels contrasts to the low levels of HDL cholesterol associated with the classic metabolic syndrome (14, 15 ).”
BackgroundPrevalence of Overweight and Obesity Among US Children, Adolescents, and Adults, 1999-2002
Hedley, A. A. (2004) · JAMA · doi:10.1001/jama.291.23.2847 · Cited by 4,460
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Hyperinsulinemia as an independent risk factor for ischemic heart disease
Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341504 · Cited by 1,699 · cited 1×
“Insulin resistance is a common metabolic abnormality that underlies type 2 diabetes mellitus (11) and is an independentriskfactorforcardiovasculardisease( 12 ,13).Insulin resistance is also linked to a variety of abnormalities associated with cardiovascular disease risk including obesity, hypertension, elevated trigly…”
BackgroundAndrogen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083 · cited 1×
“nRH AGONISTS ARE the cornerstone of treatment for metastatic prostate cancer and a routine part of management for many men with local and local-regional disease ( 1 ).”
BackgroundFerrannini, E., Natali, A., Bell, P., Cavallo-Perin, P., Lalic, N., & Mingrone, G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119628 · Cited by 898
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1992) · Medical Science Symposia Series · doi:10.1007/978-94-011-2700-4_10 · Cited by 865
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697 · cited 3×
“Consistent with earlier reports ( 5 , 8, 22), we observed that”
BackgroundMethodResultSelf-citation
Cited by
Items 101–200 of 496
Smith, M. R., Malkowicz, S. B., Chu, F. M., Forrest, J. B., SIEBER, P. R., Barnette, K. G., Rodriquez, D., & Steiner, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5517 · Cited by 84
Self-citationInsulin, insulin-like growth factors, insulin resistance, and neoplasia
Pollak, M. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.820s · Cited by 79
Martín‐Merino, E., Johansson, S., Morris, T., & Rodríguez, L. A. G. (2011) · Drug Safety · doi:10.2165/11594540-000000000-00000 · Cited by 81
“Originally used to treat men with advanced disease, ADTs are now increasingly administered to men with local or regional disease;([7]) however, they are known to increase cholesterol levels, reduce insulin sensitivity and increase body fat deposition, which are all risk factors for diabetes mellitus and cardiovascular…”
BackgroundAndrogen-deprivation Therapy and Diabetes Control Among Diabetic Men with Prostate Cancer
Keating, N. L., Liu, P.-H., O’Malley, A. J., Freedland, S. J., & Smith, M. R. (2013) · European Urology · doi:10.1016/j.eururo.2013.02.023 · Cited by 83
Self-citationEffect of androgen deprivation therapy on muscle attenuation in men with prostate cancer
Chang, D. W.-W., Joseph, D. J., Ebert, M. A., Galvao, D. A., Taaffe, D. R., Denham, J. W., Newton, R. U., & Spry, N. A. (2013) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.12124 · Cited by 78
Jayashree, S., Indumathi, D., Narasimhan, A., Sathish, S., Jayaraman, S., & Balasubramanian, K. (2013) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2012.12.016 · Cited by 82
Effectiveness of Primary Androgen-Deprivation Therapy for Clinically Localized Prostate Cancer
Potosky, A. L., Haque, R., Cassidy-Bushrow, A. E., Ulcickas Yood, M., Jiang, M., Tsai, H.-T., Luta, G., Keating, N. L., Smith, M. R., & Van Den Eeden, S. K. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.5782 · Cited by 75
Self-citationMetabolic and cardiovascular effects of androgen deprivation therapy
Hakimian, P., Blute, M., Kashanian, J., Chan, S., Silver, D., & Shabsigh, R. (2008) · BJU International · doi:10.1111/j.1464-410x.2008.07933.x · Cited by 74
Androgen Deprivation Therapy and Cardiovascular Risk
Punnen, S., Cooperberg, M. R., Sadetsky, N., & Carroll, P. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.1494 · Cited by 77
Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?
Zareba, P., Duivenvoorden, W., Leong, D. P., & Pinthus, J. H. (2015) · Therapeutic Advances in Urology · doi:10.1177/1756287215617872 · Cited by 78
Collier, A., Ghosh, S., McGlynn, B., & Hollins, G. (2012) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318201a406 · Cited by 74
Nguyen, P. L., Chen, M., Beckman, J. A., Beard, C. J., Martin, N. E., Choueiri, T. K., Hu, J. C., Hoffman, K. E., Dosoretz, D. E., Moran, B. J., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.04.067 · Cited by 76
Testosterone and cardiovascular disease: An old idea with modern clinical implications
Traish, A. M., & Kypreos, K. E. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.08.078 · Cited by 78
Storer, T. W., Miciek, R., & Travison, T. G. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.104 · Cited by 70
Limonta, P., & Manea, M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.003 · Cited by 71
Cheung, A. S., Hoermann, R., Dupuis, P., Joon, D. L., Zajac, J. D., & Grossmann, M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0200 · Cited by 69
Management of side effects of androgen deprivation therapy
Grossmann, M., & Zajac, J. D. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.004 · Cited by 69
DiBlasio, C. J., Malcolm, J. B., Derweesh, I., Womack, J. H., Kincade, M. C., Mancini, J. G. B., Ogles, M. L., Lamar, K. D., Patterson, A. L., & Wake, R. W. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.07505.x · Cited by 72
Prostate Cancer and Metabolic Syndrome: Is there a link?
McGrowder, D. A., Jackson, L. A., & Crawford, T. V. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.1.001 · Cited by 75
Saylor, P. J., Keating, N. L., & Smith, M. R. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-009-0968-y · Cited by 68
“Several small prospective studies have shown that GnRH agonists increase fasting insulin levels early in the course of GnRH agonist treatment.(63,64,66) In a prospective study of nondiabetic men, ADT significantly decreased insulin sensitivity after 12 weeks.”
BackgroundSelf-citationSaylor, P. J., Karoly, E. D., & Smith, M. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3209 · Cited by 68
“This time frame was chosen because body composition (28), lipid profile (16), and fasting insulin (14) all change within”
BackgroundMethodSelf-citationSebastiano, K. M. D., Pinthus, J. H., Duivenvoorden, W., & Mourtzakis, M. (2018) · Obesity Reviews · doi:10.1111/obr.12674 · Cited by 69
Exercise and prostate cancer: From basic science to clinical applications
Campos‐Jara, C., Sotomayor, P. C., Jerez‐Mayorga, D., González‐Gallego, J., Schmidt, C. B., Schmidt, K., Banzer, W. E., & Godoy, A. (2018) · The Prostate · doi:10.1002/pros.23502 · Cited by 70
Tsai, H., Keating, N. L., Eeden, S. K. V. D., Haque, R., Cassidy‐Bushrow, A. E., Yood, M. U., Smith, M. R., & Potosky, A. L. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.12.027 · Cited by 64
Self-citationRyan, J., & Gajraj, J. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2011.12.001 · Cited by 63
Indumathi, D., Jayashree, S., Jayaraman, S., Sathish, S., Mayilvanan, C., Narasimhan, A., & Balasubramanian, K. (2013) · Human & Experimental Toxicology · doi:10.1177/0960327112470273 · Cited by 62
Freedland, S. J., Howard, L. E., Allen, J., Smith, J. L., Stout, J., Aronson, W. J., Inman, B. A., Armstrong, A. J., George, D. J., Westman, E. C., et al. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0126-5 · Cited by 62
White, I. D., Wilson, J. M., Aslet, P., Baxter, A., Birtle, A. J., Challacombe, B. J., Coe, J., Grover, L., Payne, H. A., Russell, S., et al. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12512 · Cited by 59
Owen, P. J., Daly, R. M., Livingston, P. M., & Fraser, S. F. (2017) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.69 · Cited by 62
Hormonal treatment and quality of life of prostate cancer patients: new evidence
Tucci, M., Leone, G., Buttigliero, C., Zichi, C., Stefano, R. F. D., Pignataro, D., Vignani, F., Scagliotti, G. V., & Maïo, M. D. (2018) · Minerva Urology and Nephrology · doi:10.23736/s0393-2249.17.03066-1 · Cited by 58
“disorders such as decreased insulin sensitivity (17,20,23-27), diabetes (17,20,25), increase of cholesterol levels and fat body mass (17,20,25,26,28).”
BackgroundMoróte, J., Gómez‐Caamaño, A., Alvarez-Ossorio, J. L., Pesqueira, D., Tabernero, Á., Veiga, F. G., Lorente, J. A., Porras, M., Encinas, J. J. L., Ribal, M. J., et al. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.12.086 · Cited by 62
“that ADT promotes the development of metabolic disturbances, particularly insulin resistance.(14,15)”
Cheung, A. S., Pattison, D. A., Bretherton, I., Hoermann, R., Joon, D. L., Ho, E., Jenkins, T., Hamilton, E. J., Bate, K. L., Chan, I., et al. (2013) · Andrology · doi:10.1111/j.2047-2927.2013.00093.x · Cited by 61
“, 2011), insulin resistance (Smith et al., 2006; Hamilton et al., 2011) and accelerated bone loss (Greenspan et al.”
BackgroundInfluentialGalvao, D. A., Taaffe, D. R., Spry, N. A., Joseph, D. J., & Newton, R. U. (2011) · The Journal of Urology · doi:10.1016/j.juro.2011.05.055 · Cited by 59
Auriemma, R. S., Galdiero, M., Vitale, P., Granieri, L., Calzo, F. L., Salzano, C., Ferreri, L., Pivonello, C., Cariati, F., Coppola, G., et al. (2015) · Neuroendocrinology · doi:10.1159/000371851 · Cited by 61
Androgen deprivation therapy complications
Allan, C. A., Collins, V., Frydenberg, M., McLachlan, R. I., & Matthiesson, K. L. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0467 · Cited by 60
Conteduca, V., Lorenzo, G. D., Tartarone, A., & Aieta, M. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.09.008 · Cited by 61
Keyes, M., Merrick, G. S., Frank, S. J., Grimm, P., & Zeléfsky, M. J. (2017) · Brachytherapy · doi:10.1016/j.brachy.2016.11.017 · Cited by 58
“In addition, ADT is documented to elevate blood pressure, elevate fasting glucose and fasting insulin by 26%, decrease insulin sensitivity by 13%, and increase diabetes by 44% (40, 42, 47).”
Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
Siddiqui, Z. A., & Krauss, D. J. (2018) · Translational Andrology and Urology · doi:10.21037/tau.2018.01.06 · Cited by 57
“In combination with mechanistic information suggesting that ADT causes insulin resistance (62), unfavorable blood lipid profiles, body composition changes (63,64), and skeletal resorption (65), the above clinical evidence”
BackgroundEstrogenic side effects of androgen deprivation therapy.
Guise, T. A., Oefelein, M. G., Eastham, J. A., Cookson, M. S., Higano, C. S., & Smith, M. R. (2007) · Europe PMC (PubMed Central) · Cited by 56
Self-citationEffects of testosterone replacement and its pharmacogenetics on physical performance and metabolism
Zitzmann, M. (2008) · Asian Journal of Andrology · doi:10.1111/j.1745-7262.2008.00405.x · Cited by 54
Androgen deprivation therapy is associated with diabetes: Evidence from meta‐analysis
Wang, H., Sun, X., Zhao, L., Chen, X., & Zhao, J. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12472 · Cited by 53
Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
Harle, L., Maggio, M., Shahani, S., Braga‐Basaria, M., & Basaria, S. S. (2006) · PubMed · Cited by 55
Traish, A. M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-70178-3_22 · Cited by 58
LHRH Agonists for the Treatment of Prostate Cancer: 2012.
Lepor, H., & Shore, N. D. (2012) · Europe PMC (PubMed Central) · Cited by 67
Adverse health effects of testosterone deficiency (TD) in men
Traish, A. M. (2014) · Steroids · doi:10.1016/j.steroids.2014.05.010 · Cited by 54
The Emerging Link Between Hypogonadism and Metabolic Syndrome
Guay, A. T. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.006015 · Cited by 50
microRNAs and cancer metabolism reprogramming: the paradigm of metformin.
Pulito, C., Donzelli, S., Muti, P. C., Puzzo, L., Strano, S., & Blandino, G. (2014) · PubMed Central · doi:10.3978/j.issn.2305-5839.2014.06.03 · Cited by 54
“Subsequently, metformin treatment may synergize with common anti-androgen therapies, which are usually prescribed for metastatic prostate cancer treatment (53).”
BackgroundAcute testosterone deprivation reduces insulin sensitivity in men
Rubinow, K. B., Snyder, C. N., Amory, J. K., Hoofnagle, A. N., & Page, S. T. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04189.x · Cited by 48
Kim, H. S., Moreira, D. M., Smith, M. R., Presti, J. C., Aronson, W. J., Terris, M. K., Kane, C. J., Amling, C. L., & Freedland, S. J. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09679.x · Cited by 49
Self-citationØstergren, P. B., Kistorp, C., Fode, M. M., Bennedbæk, F. N., Faber, J. O., & Sønksen, J. (2018) · British Journal of Urology · doi:10.1111/bju.14609 · Cited by 49
Androgen Deprivation Therapy in Prostate Cancer: Focusing on Sexual Side Effects
Corona, G., Gacci, M., Baldi, E., Mancina, R., Forti, G., & Maggi, M. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02590.x · Cited by 50
Complications of androgen deprivation therapy in prostate cancer
Schwandt, A., & Garcia, J. A. (2009) · Current Opinion in Urology · doi:10.1097/mou.0b013e32832a082c · Cited by 49
Mitsuzuka, K., Kyan, A., Toshikazu, S. A. T. O., Orikasa, K., Miyazato, M., Aoki, H., Kakoi, N., Narita, S., Koie, T., Namima, T., et al. (2015) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2015.50 · Cited by 43
Evolution of sexually dimorphic longevity in humans
Gems, D. (2014) · Aging · doi:10.18632/aging.100640 · Cited by 44
“ADT can also increase insulin resistance, hyperinsulemia and hyperglycemia [58].”
BackgroundEfstathiou, J. A., Chen, M., Renshaw, A. A., Loffredo, M. J., & D'Amico, A. V. (2007) · Cancer · doi:10.1002/cncr.22564 · Cited by 43
Androgen deprivation therapy and side effects: are GnRH antagonists safer?
Freedland, S. J., & Abrahamsson, P. (2020) · Asian Journal of Andrology · doi:10.4103/aja.aja_22_20 · Cited by 45
Hypogonadism, Type-2 Diabetes Mellitus, and Bone Health: A Narrative Review
Russo, V., Chen, R., & Armamento‐Villareal, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.607240 · Cited by 49
Kosuri, S., Akhtar, N., Smith, M. R., Osborne, J. R., & Tagawa, S. T. (2012) · Advances in Urology · doi:10.1155/2012/921674 · Cited by 40
Self-citationSex steroids and glucose metabolism
Allan, C. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122589 · Cited by 43
Hvid, T., Winding, K., Rinnov, A., Dejgaard, T., Thomsen, C., Iversen, P., Brasso, K., Mikines, K. J., van Hall, G., Lindegaard, B., et al. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-12-0393 · Cited by 38
“Even though insulin resistance is a well-known and serious side effect of ADT in prostate cancer patients (Basaria et al. 2006, Smith et al. 2006, 2008a, Hamilton et al. 2011), no other studies have investigated the effect of a training intervention on insulin sensitivity in this group of patients.”
Potential side effects of androgen deprivation treatment in sex offenders.
Giltay, E. J., & Gooren, L. J. (2009) · PubMed · Cited by 46
Ethical and medical considerations of androgen deprivation treatment of sex offenders
Gooren, L. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1540 · Cited by 39
“55) (91, 94) Cardiovascular disease/mortality Incident coronary heart disease 4.”
BackgroundMetabolomic effects of androgen deprivation therapy treatment for prostate cancer
Chi, J., Lin, P., Tolstikov, V., Oyekunle, T. O., Chen, E. Y.-S., Bussberg, V., Greenwood, B. P., Sarangarajan, R., Narain, N. R., Kiebish, M. A., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3016 · Cited by 42
Miner, M. M., & Seftel, A. D. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01317.x · Cited by 39
Saad, F. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2354 · Cited by 39
“Significant changes in body composition such as decrease in lean mass and increase in fat mass were noted 12 weeks post-ADT [58].”
BackgroundPharmacotherapeutic Management of Locally Advanced Prostate Cancer: Current Status
Martin, J. M., Supiot, S., & Berthold, D. (2011) · Drugs · doi:10.2165/11591500-000000000-00000 · Cited by 39
Association between testosterone levels and the metabolic syndrome in adult men
Grosman, H., Rosales, M., Fabre, B. R., Nolazco, C., Mazza, O., Berg, G. A., & Mesch, V. (2014) · The Aging Male · doi:10.3109/13685538.2014.913561 · Cited by 39
“androgen deprivation therapy, there was an increment in all the lipids parameters studied, total cholesterol, LDL-chol, HDL-chol and triglycerides [29,39].”
BackgroundIacovelli, R., Verri, E., Rocca, M. C., Aurilio, G., Cullurà, D., COBELLI, O. D., & Nolè, F. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.106 · Cited by 37
“Smith and colleagues investigated the mechanisms through which ADT has been suspected to heighten cardiovascular risk, and these include an increased fat mass, low-density lipoprotein and total cholesterol levels, triglycerides and insulin resistance [3–5].”
BackgroundMetabolic effects of androgen deprivation therapy
Choi, S. M., & Kam, S. C. (2015) · Korean journal of urology · doi:10.4111/kju.2015.56.1.12 · Cited by 42
“[20] also reported on 25 patients who were diagnosed with locally advanced or recurrent prostate cancer.”
BackgroundMethodInfluentialGalvao, D. A., Taaffe, D. R., Spry, N. A., Joseph, D., & Newton, R. U. (2009) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2009.12 · Cited by 40
“6% Lean body mass k 2% Smith et al. (2006)(9) Prospective 12 weeks 25 (68) LHRHa+antiandrogen ISI k 12.9%, FPI m 25.9% % Body fat m 4.3%, % lean body mass k 1.4% Total cholesterol m 9.4%, HDL cholesterol m 9.9%, LDL cholesterol m 8.7%, triglycerides m 23.0% Basaria et al. (2006)(14) Cross-sectional 18, PC (70) bilater…”
BackgroundInfluentialHormone Therapy for Prostate Cancer
Nelson, J. B. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00109-2 · Cited by 41
Androgen deprivation therapy and cardiovascular disease
Melloni, C., & Roe, M. T. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.02.010 · Cited by 39
Trost, L. W., Şerefoğlu, E. C., Gökçe, A., Linder, B. J., Sartor, A. O., & Hellstrom, W. J. G. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12036 · Cited by 40
Hernández‐Mijares, A., García-Malpartida, K., Solá-Izquierdo, E., Bañuls, C., Rocha, M., Gómez-Martínez, M. J., Mármol, R., & Víctor, V. M. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01705.x · Cited by 38
Lam, T., Birzniece, V., McLean, M. P., Gurney, H., Hayden, A. J., & Cheema, B. S. (2020) · Sports Medicine - Open · doi:10.1186/s40798-020-0242-8 · Cited by 38
Cardiovascular Toxicity of Androgen Deprivation Therapy
Boland, J. L., Choi, W., Lee, M., & Lin, J. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01561-9 · Cited by 35
Beydoun, N., Bucci, J. A., Chin, Y. S., Spry, N. A., Newton, R. U., & Galvao, D. A. (2013) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.12115 · Cited by 35
Galvao, D. A., Spry, N. A., Taaffe, D. R., Denham, J. W., Joseph, D. J., Lamb, D. S., Levin, G., Duchesne, G. M., & Newton, R. U. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-419 · Cited by 37
“negative lipoprotein profile, reduced insulin sensitivity, abdominal obesity) [2-7].”
Guo, Z., Huang, Y., Gong, L., Gan, S., Chan, F. L., Gu, C., Xiang, S., & Wang, S. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0059-4 · Cited by 36
Aggarwal, R. R., Ryan, C. J., & Chan, J. M. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2011.05.001 · Cited by 35
“These include obesity and increases in fasting serum insulin and glucose levels, which have been used as surrogate measures of insulin resistance (IR) in prior studies [1–7].”
MethodRoles of Testosterone Replacement in Cardiac Ischemia–Reperfusion Injury
Pongkan, W., Chattipakorn, S. C., & Chattipakorn, N. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415587977 · Cited by 37
Metabolic Syndrome and Prostate Cancer: A Review
Nobes, J. P., Langley, S. E. M., & Laing, R. W. (2008) · Clinical Oncology · doi:10.1016/j.clon.2008.11.013 · Cited by 36
Exercise and Prostate Cancer: Evidence and Proposed Mechanisms for Disease Modification
Hayes, B. D., Brady, L., Pollak, M., & Finn, S. P. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0223 · Cited by 38
Cardiovascular risk during hormonal treatment in patients with prostate cancer
Poppel, H. V. (2011) · Cancer Management and Research · doi:10.2147/cmr.s16893 · Cited by 34
Controversies in testosterone replacement therapy: testosterone and cardiovascular disease
Hwang, K., & Miner, M. M. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.146968 · Cited by 37
Kiwata, J. L., Dorff, T. B., Schroeder, E. T., Gross, M. E., & Dieli-Conwright, C. M. (2016) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.25 · Cited by 37
Crawley, D., Garmo, H., Rudman, S. M., Stattin, P. E., Häggström, C., Zethelius, B., Holmberg, L., Adolfsson, J., & Hemelrijck, M. V. (2016) · International Journal of Cancer · doi:10.1002/ijc.30403 · Cited by 32
“ADT increases the prevalence of metabolic syndrome components such as decreased insulin sensitivity and increased body fat.(12) We have previously undertaken a meta-analysis to quantify the association between ADT and metabolic syndrome.”
Crawley, D., Chamberlain, F., Garmo, H., Rudman, S. M., Zethelius, B., Holmberg, L., Adolfsson, J., Stattin, P. E., Carroll, P., & Hemelrijck, M. V. (2018) · ecancermedicalscience · doi:10.3332/ecancer.2018.802 · Cited by 33
“ADT has been shown to induce a metabolic-like syndrome, in which patients have decreased insulin sensitivity and increased body fat [56].”
BackgroundLandmarks in hormonal therapy for prostate cancer
Hammerer, P. G., & Madersbacher, S. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11431.x · Cited by 39
Emerging cardiometabolic complications of androgen deprivation therapy
Choong, K., & Basaria, S. S. (2010) · The Aging Male · doi:10.3109/13685530903410625 · Cited by 33
“In one study, triglyceride levels increased by 23% [30], while another study showed increments of 26.”
BackgroundThe Metabolic Syndrome in Central Hypogonadotrophic Hypogonadism
Dwyer, A. A., & Quinton, R. (2018) · Frontiers of hormone research · doi:10.1159/000485998 · Cited by 32
Li, Q., Gui-zhong, Y., Wang, Y., Zhang, X., Sang, Q., Wang, H., Zhao, X., Xing, Q., He, L., & Wang, L. (2011) · Human Genetics · doi:10.1007/s00439-011-0954-4 · Cited by 34
“It is well documented that GnRH agonists could increase the risk of diabetes mellitus and cardiovascular disease and GnRH analog administration induces a significant reduction in insulin sensitivity in healthy premenopausal women (Palomba et al. 2004; Smith et al. 2006).”
BackgroundThe continued debate: Intermittent vs. continuous hormonal ablation for metastatic prostate cancer
Gleave, M. E., Klotz, L. H., & Taneja, S. S. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.07.025 · Cited by 30
“In recent years, any authors have reported on additional complications f hormonal ablation including osteoporosis, altered lipid rofiles, insulin resistance, depression, cognitive changes, nd, perhaps, increased risk of cardiovascular disease [6–14].”
BackgroundRadiotherapy for high-risk prostate cancer
Mohiuddin, J. J., Baker, B. R., & Chen, R. C. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.25 · Cited by 31
Lee, M., Hong, H., Kim, W., Zhang, L., Friedlander, T. W., Fong, L., Lin, A. M., Small, E. J., Wei, X. X., Rodvelt, T. J., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.09.013 · Cited by 28
Lebrét, T., Coloby, P. J., Descotes, J. L., Droupy, S., Geraud, M., & TOMBAL, B. F. (2010) · Urology · doi:10.1016/j.urology.2010.07.483 · Cited by 29
Liang, Z. C., Zhu, J. W., Duo, X., Shi, S., Xu, Y., Yang, Y., Hu, R., Lu, Y., Zhang, W., Ou, N., et al. (2019) · Andrology · doi:10.1111/andr.12731 · Cited by 30
“Since then several observational studies and randomized controlled trials have also assessed the association between risk of cardiovascular events and ADT, yet have demonstrated equivocal findings [10-12].”
BackgroundAndrogen deprivation therapy in prostate cancer: anticipated side-effects and their management
Kim, H. S., & Freedland, S. J. (2010) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e32833bd913 · Cited by 32
Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man
Inoue, T., Zakikhani, M., David, S., Algire, C., Blouin, M., & Pollak, M. (2010) · The Prostate · doi:10.1002/pros.21198 · Cited by 31
Möhlig, M., Arafat, A. M., Osterhoff, M. A., Isken, F., Weickert, M. O., Spranger, J., Pfeiffer, A. F. H., & Schöfl, C. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1022 · Cited by 30
Metadata
- Authors
- Smith, M. R., Lee, H., & Nathan, D. M.
- Affiliations
- Massachusetts General Hospital (US)
- Corresponding author
- Smith, Matthew R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-04
- Volume
- 91
- Issue
- 4
- Pages
- 1305-1308
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2129509910
- Cited by
- 493
- References
- 25
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 14 · 2023: 12 · 2022: 13 · 2021: 9 · 2020: 14 · 2019: 15 · 2018: 20 · 2017: 25 · 2016: 24 · 2015: 26 · 2014: 26 · 2013: 35 · 2012: 46
- FWCI
- 32.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Prostate Cancer Foundation
- Massachusetts General Hospital
- National Institutes of Health
- National Cancer Institute (P50 CA 90381, P50CA090381)
- National Center for Research Resources (M01RR001066, M01-RR01066)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- insulin sensitivity, prostate cancer, combined androgen blockade, GnRH agonist, leuprolide, bicalutamide, fat mass, insulin resistance, diabetes risk, cardiovascular risk, fasting insulin, HbA1c
- MeSH terms
- Adipose Tissue, Adult, Androgen Antagonists, Anthropometry, Blood Glucose, Body Composition, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Gonadotropin-Releasing Hormone, Lipids, Male, Prospective Studies, Prostatic Neoplasms, Testosterone, Biomarkers, Absorptiometry, Photon, Treatment Outcome, Antineoplastic Agents, Hormonal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.